Chia Tai Tianqing Pharmaceutical Group Co., Ltd.;Lianyungang Runzhong Pharmaceutical Co., Ltd.;Centaurus Biopharma Co., Ltd.
发明人:
Zhou Zhou,Aiming Zhang,Xiquan Zhang,Huadong Yao
申请号：
US16310369
公开号：
US20190330215A1
申请日:
2017.06.15
申请国别(地区):
US
年份:
2019
代理人:
摘要：
The present application relates to the field of pharmaceutical chemistry. The application specifically relates to a crystal form A and crystal form B of a pyrrolopyrimidine (formula I) for preparing a JAK inhibitor. The application further relates to a method for preparing the crystal form A and crystal form B, a crystalline composition comprising the crystal form A or crystal form B, a pharmaceutical composition comprising the crystal form A, crystal form B, or crystalline composition, and a pharmaceutical application of the pharmaceutical composition, the crystal form A, and the crystal form B. The crystal form A and crystal form B of the application has the advantages of high purity, high crystallinity, and good stability.
